Click amount to donate direct to CounterPunch
  • $25
  • $50
  • $100
  • $500
  • $other
  • use PayPal
Please Support CounterPunch’s Annual Fund Drive
We don’t run corporate ads. We don’t shake our readers down for money every month or every quarter like some other sites out there. We only ask you once a year, but when we ask we mean it. So, please, help as much as you can. We provide our site for free to all, but the bandwidth we pay to do so doesn’t come cheap. All contributions are tax-deductible.
FacebookTwitterGoogle+RedditEmail

A Decade of Questions Over a Paxil Study Vindicated

In the last few years, highly promoted drugs like Vioxx, Bextra, Baycol, Trovan, Meridia, Seldane, Hismanal, Darvon, Mylotarg, Lotronex, Propulsid, phenylpropanolamine (PPA), phenacetin, Raxar and Redux have been withdrawn for safety risks after millions used them. Sorry about that. Others like Avandia, Cylert, Ketek and Xarelto are under serious safety clouds.

But Big Pharma insists it is unaware of drugs’ true risks until a wide swath of the population uses them and “safety signals” emerge. Facts sometimes suggest otherwise.

In 1977, almost thirty years before Merck admitted its bone drug Fosamax caused jawbone death, its bone scientist observed the action in rats. (The “anti-fracture” drug also causes fractures.)

Years before the label of the antipsychotic Seroquel was changed in 2011 to warn the drug “should be avoided” in combination with at least 12 other medications because of heart risks, at least 99 articles in the U.S. National Library of Medicine linked the drug to “sudden death,”  “QT prolongation” (a heart disturbance that can lead to death), “cardiac arrest” and “death.” In many cases, the Pharma companies “discover” the problems after the drug patent has conveniently expired.

Then there’s Paxil. Paroxetine was a top selling SSRI antidepressant drug for GSK during the “happy pill” craze when Big Pharma was telling everyone they had “depression.” But in 2004, soon after its approval, the New York Attorney General charged that research about the drug published in the Journal of the American Academy of Child and Adolescent Psychiatry (known as “Study 329”) buried the drug’s true risks of suicide in adolescents.

And there were more questions about the research. Former Boston Globe reporter Alison Bass and others reported that the paper was not even written by the 22 doctors and researchers listed as “authors” but by a medical communication company hired by GSK. (Ghostwriting helped make Vioxx, Neurontin, hormone replacement therapy and even the flame retardant chemical deca [Deca-BDE] appear safe, according to published reports.) “You did a superb job with this,” wrote the Paxil paper’s first “author” Martin Keller of Brown University to Sally Laden, a ghostwriter working for Scientific Therapeutics Information. “It is excellent. Enclosed are rather minor changes from me.”

In 2006, “author” Martin Keller, former Professor Emeritus of Psychiatry at Brown, acknowledged that GSK had given him tens of thousands of dollars during and after the time the study was conducted.

There were also questions about where the research appeared. The Journal of the American Academy of Child and Adolescent Psychiatry is a publication of the American Academy of Child and Adolescent Psychiatry which lists the funders of its “treatment guidelines” for children and adolescents with bipolar disorder as Abbott, AstraZeneca, Eli Lilly, Forest, Janssen, Novartis and Pfizer.

Almost fifteen years after the questionable research was published, the furor had not died down. In 2014, two members of the American Academy of Child and Adolescent Psychiatry, Edmund Levin and George Stewart, asked the editor of the Academy’s journal why the discredited paper was still standing and had not been retracted. (A quick look at other scientific papers identified in the press as ghostwritten shows that few are retracted and most are standing, to deceive future generations.)

Then, in September 2015, when many reporters, psychiatrists, researchers and professors had given up the Paxil fight, the British Medical Journal (BMJ) published a reanalysis that amounted to a reversal of the original study. The new research demonstrated that Paxil indeed increases risks of suicide in young people and adolescents.

The reanalysis of Paxil’s suicide risks in the young is a victory for safety activists, medical reporters, the public and freedom of the press. But many pro-pill doctors continue to fight evidence of Paxil’s suicide risks and similar SSRIs. “There is a very reasonable possibility that it has discouraged patients from taking antidepressants and physicians from prescribing these medications [and] the government should rescind the black-box warning on antidepressants altogether,” Richard A. Friedman, a professor of clinical psychiatry at Weill Cornell Medical wrote in the New York Times a month before the Paxil reanalysis.

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

October 15, 2018
Rob Urie
Climate Crisis is Upon Us
Conn Hallinan
Syria’s Chessboard
Patrick Cockburn
The Saudi Atrocities in Yemen are a Worse Story Than the Disappearance of Jamal Khashoggi
Sheldon Richman
Trump’s Middle East Delusions Persist
Justin T. McPhee
Uberrima Fides? Witness K, East Timor and the Economy of Espionage
Tom Gill
Spain’s Left Turn?
Jeff Cohen
Few Democrats Offer Alternatives to War-Weary Voters
Dean Baker
Corporate Debt Scares
Gary Leupp
The Khashoggi Affair and and the Anti-Iran Axis
Russell Mokhiber
Sarah Chayes Calls on West Virginians to Write In No More Manchins
Clark T. Scott
Acclimated Behaviorisms
Kary Love
Evolution of Religion
Colin Todhunter
From GM Potatoes to Glyphosate: Regulatory Delinquency and Toxic Agriculture
Binoy Kampmark
Evacuating Nauru: Médecins Sans Frontières and Australia’s Refugee Dilemma
Marvin Kitman
The Kitman Plan for Peace in the Middle East: Two Proposals
Weekend Edition
October 12, 2018
Friday - Sunday
Becky Grant
My History with Alexander Cockburn and The Financial Future of CounterPunch
Paul Street
For Popular Sovereignty, Beyond Absurdity
Nick Pemberton
The Colonial Pantsuit: What We Didn’t Want to Know About Africa
Jeffrey St. Clair
The Summer of No Return
Jeff Halper
Choices Made: From Zionist Settler Colonialism to Decolonization
Gary Leupp
The Khashoggi Incident: Trump’s Special Relationship With the Saudi Monarchy
Andrew Levine
Democrats: Boost, Knock, Enthuse
Barbara Kantz
The Deportation Crisis: Report From Long Island
Doug Johnson
Nate Silver and 538’s Measurable 3.5% Democratic Bias and the 2018 House Race
Gwen Carr
This Stops Today: Seeking Justice for My Son Eric Garner
Robert Hunziker
Peak Carbon Emissions By 2020, or Else!
Arshad Khan
Is There Hope on a World Warming at 1.5 Degrees Celsius?
David Rosen
Packing the Supreme Court in the 21stCentury
Brian Cloughley
Trump’s Threats of Death and Destruction
Joel A. Harrison
The Case for a Non-Profit Single-Payer Healthcare System
Ramzy Baroud
That Single Line of Blood: Nassir al-Mosabeh and Mohammed al-Durrah
Zhivko Illeieff
Addiction and Microtargeting: How “Social” Networks Expose us to Manipulation
ADRIAN KUZMINSKI
What is Truth?
Michael Doliner
Were the Constitution and the Bill of Rights a Mistake?
Victor Grossman
Cassandra Calls
Ralph E. Shaffer
Could Kavanaugh’s Confirmation Hearing Ended Differently?
Vanessa Cid
Our Everyday Family Separations
Walaa Al Ghussein
The Risks of Being a Journalist in Gaza
Ron Jacobs
Betrayal and Treachery—The Extremism of Moderates
James Munson
Identity Politics and the Ruling Class
P. Sainath
The Floods of Kerala: the Bank That Went Under…Almost
Ariel Dorfman
How We Roasted Donald Duck, Disney’s Agent of Imperialism
Joe Emersberger
Ecuadorian President Lenin Moreno’s Assault on Human Rights and Judicial Independence
Ed Meek
White Victimhood: Brett Kavanaugh and the New GOP Brand
Andrew McLean, MD
A Call for “Open Space”
FacebookTwitterGoogle+RedditEmail